Global

Recent News Releases

CSL Behring News Releases

CSL Behring Subscribe to alerts

CSL Limited Financial News

19 April 2017
Therapeutic Goods Administration Approves AFSTYLA® - CSL Behring’s Novel Recombinant Haemophilia A Treatment
Global biotherapeutics leader, CSL Behring today announced that the Australian Therapeutic Goods Administration (TGA) has approved AFSTYLA® [lonoctocog alfa]. More.

10 April 2017
Improving Access to Lifesaving Treatments for Bleeding Disorders in the Developing World

CSL Behring marks World Hemophilia Day by donating its bleeding disorders medicines to the World Federation of Hemophilia (WFH).

More.

05 April 2017
CSL Behring Presents Data on RAPID Trial Extension and Supports Alpha-1 International Research and Patient Conference
CSL Behring continues legacy of support for Alpha-1 Community with Global Research Conference and Patient Congress Sponsorship. More.

Media Resources

CSL Behring Company Information CSL Behring
Company Information >
CSL Behring Media Contacts CSL Behring
Media Contacts >
CSL Behring Social Media CSL Behring
Social Media >
CSL Behring MultiMedia Library CSL Behring
Images and Videos >



Our Patients' Stories




CSL Behring at a Glance

CSL Behring at a glance







Share
LinkedIn Twitter Facebook Google+